SAGE-217 is an investigational medication which is under development by SAGE Therapeutics for the treatment of major depressive disorder, postpartum depression, essential tremor, Parkinson's disease, insomnia, and seizures.[2][3] It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABAA receptor.
I am looking after this compound since more then one year, it seems to be a great hope for all people suffering of depression.
All trials went in a really amazing way, results are great.
Only problem is, how long should I wait to see if this works?
- 02 May 2019 Sage Therapeutics plans a placebo-controlled re-treatment trial for Major depressive disorder (Monotherapy), in the third quarter of 2019
- 23 Mar 2019 Sage Therapeutics completes a phase II trial in Bipolar Disorder in the US (NCT03692910)
- 27 Feb 2019 Sage Therapeutics initiates enrolment in a phase III trial for Major depressive disorder (NCT03864614)
Anybody interested in this compound?
Edited by diegot, 01 July 2019 - 11:35 AM.